Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study
This study assessed the comparative adherence of these ERAs for PAH in Australian patients.Methods: This retrospective, observational study used data for adults with PAH from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset (01/2006-10/2020). The primary outcome was treatment adherence (ie, receiving ≥80% of ERA doses over 12 months). Secondary outcomes were time to treatment change (add-on or switch) and overall survival.Results: The study included 436 patients who took bosentan (n = 200), ambrisentan (n = 69), or macitentan (n = 167). Treatment adherence was significantly greater in patients who...
Source: Journal of Medical Economics - March 15, 2024 Category: Health Management Authors: Edmund Lau Eugene Kotlyar Yogeshwar Makanji Dae Young Yu Jin Yu Tan Jeremy Casorso Mahsa H Kouhkamari Sooyeol Lim David Bin-Chia Wu Paul Bloomfield Source Type: research

Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma
Conclusion: This simulation demonstrates that treatment with toripalimab generates savings that enable budget-neutral funding for up to an additional 252 regimens with toripalimab-gemcitabine-cisplatin for one full year, the equivalent of approximately 21% of the 2024 incident cases of R/M NPC in the US.PMID:38488887 | DOI:10.1080/13696998.2024.2331905 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 15, 2024 Category: Health Management Authors: Karen MacDonald Marc Pondel Ivo Abraham Source Type: research

The economic burden of systemic lupus erythematosus in Mexico
CONCLUSION: The findings pointed out the substantial economic burden associated with SLE, including the costs of disease progression and SLE transient events, such as flare-ups, infections, and organ damage, in addition to productivity loss due to work capacity impairment.PMID:38468477 | DOI:10.1080/13696998.2024.2322263 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Lilia Andrade-Ortega Margarita Portela Gabriel Medrano Ram írez Source Type: research

Clinical and economic burden of systemic lupus erythematosus in Colombia
CONCLUSION: The burden of SLE in Colombia over five years is substantially high, mainly due to the consequences of economic loss because it affects women and men of working age, in addition to the costs of SLE management and its consequences, such as flares, infection, and organ damage. Our COI indicated that disease management costs among patients with moderate and severe SLE were substantially higher than those among patients with a mild phenotype. Therefore, more attention should be paid to limiting the progression of SLE and the occurrence of flares, with the need for further economic evaluation of novel treatment stra...
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Gerardo Quintana Diana Gil Pedro Santos Diana Fernandez Source Type: research

Economic burden of systemic lupus erythematosus in Malaysia
CONCLUSION: Our study demonstrated the substantial economic burden of SLE in Malaysia over a time horizon of 5 years. It affects adults of working age, in addition to the costs of SLE management and its consequences, such as flares, infection, and organ damage. Our COI model indicated that disease management costs among patients with higher disease severity were higher than those among patients with a mild phenotype. Hence, more attetion should be paid to limiting the progression of SLE and the occurrence of flares, with the need for further economic evaluation of novel treatments that could lead to better outcomes.PMID:38...
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Ang Yu Joe Mollyza Mohd Zain Habibah Mohd Yusoof Cheng Lay Teh Asmah Binti Mohd Xiang Ting Khor Liza Binti Mohd Isa Source Type: research

The economic burden of systemic lupus erythematosus in Taiwan
CONCLUSION: The findings demonstrated that the burden of SLE in Taiwan over a time horizon of 5 years is substantially high, mainly due to the consequences of economic loss as it affects women and men during their working age, in addition to the costs of SLE management and its consequences, such as flares, infection, and organ damage. Therefore, more attention should be paid to limiting the progression of SLE and the occurrence of flares, and further economic evaluations are necessary to assess novel treatment strategies that could control the disease.PMID:38468480 | DOI:10.1080/13696998.2024.2317118 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Song-Chou Hsieh Der-Yuan Chen Source Type: research

Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates
CONCLUSION: The addition of anifrolumab to SoC is a cost-effective option versus belimumab for the treatment of adult patients with active, autoantibody-positive SLE, despite being allocated to SoC. Cost-effectiveness was demonstrated by a reduction in complications and organ damage, which reflected costs and outcomes.PMID:38468481 | DOI:10.1080/13696998.2024.2320603 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Ahmed Abogamal Waleed Walid Al Shehhy Mohamed Farghaly Source Type: research

The economic burden of systemic lupus erythematosus in United Arab Emirates
CONCLUSION: Our findings demonstrate that the burden of SLE in the UAE is enormous, mainly because of the costly complications and productivity loss. More awareness should be created to limit the progression of SLE and reduce the occurrence of flares, necessitating further economic evaluations of novel treatments that could help reduce the economic consequences of SLE in the UAE.PMID:38468482 | DOI:10.1080/13696998.2024.2318996 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Atheer Alansari Suad Hannawi Afra Aldhaheri Noura Zamani Gihan Hamdy Elsisi Sara Aldalal Waiel Al Naeem Mohamed Farghaly Source Type: research

Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden
CONCLUSIONS: This partitioned survival analysis suggests that pembrolizumab plus lenvatinib is cost effective compared with chemotherapy in Sweden for women with advanced or recurrent endometrial carcinoma following previous systemic therapy. Results were robust to mismatch repair status and to changes in parameters/assumptions.PMID:38470404 | DOI:10.1080/13696998.2024.2329022 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Lewis Ralph Kate Young Navneet Upadhyay Vimalanand Shrikant Prabhu Christina Ljungcrantz Rachid Massaad Ruifeng Xu Anna Giertz Adil Merchant Robert Orlowski Linda Duska Source Type: research

Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective
CONCLUSIONS: Nivolumab is estimated to be a life-extending and cost-effective option for adjuvant treatment of MIUC for patients who are at high risk of recurrence after undergoing radical resection in the United States. Using a threshold of $150,000/QALY, the cost-effectiveness conclusions remained consistent across the scenario and sensitivity analyses conducted.PMID:38470512 | DOI:10.1080/13696998.2024.2329019 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Thor-Henrik Brodtkorb Christopher Knight Farzam Kamgar Siguroli Teitsson Murat Kurt Miraj Y Patel Tayla Poretta Ronac Mamtani Stephen Palmer Source Type: research

The economic burden of systemic lupus erythematosus in Mexico
CONCLUSION: The findings pointed out the substantial economic burden associated with SLE, including the costs of disease progression and SLE transient events, such as flare-ups, infections, and organ damage, in addition to productivity loss due to work capacity impairment.PMID:38468477 | DOI:10.1080/13696998.2024.2322263 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Lilia Andrade-Ortega Margarita Portela Gabriel Medrano Ram írez Source Type: research

Clinical and economic burden of systemic lupus erythematosus in Colombia
CONCLUSION: The burden of SLE in Colombia over five years is substantially high, mainly due to the consequences of economic loss because it affects women and men of working age, in addition to the costs of SLE management and its consequences, such as flares, infection, and organ damage. Our COI indicated that disease management costs among patients with moderate and severe SLE were substantially higher than those among patients with a mild phenotype. Therefore, more attention should be paid to limiting the progression of SLE and the occurrence of flares, with the need for further economic evaluation of novel treatment stra...
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Gerardo Quintana Diana Gil Pedro Santos Diana Fernandez Source Type: research

Economic burden of systemic lupus erythematosus in Malaysia
CONCLUSION: Our study demonstrated the substantial economic burden of SLE in Malaysia over a time horizon of 5 years. It affects adults of working age, in addition to the costs of SLE management and its consequences, such as flares, infection, and organ damage. Our COI model indicated that disease management costs among patients with higher disease severity were higher than those among patients with a mild phenotype. Hence, more attetion should be paid to limiting the progression of SLE and the occurrence of flares, with the need for further economic evaluation of novel treatments that could lead to better outcomes.PMID:38...
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Ang Yu Joe Mollyza Mohd Zain Habibah Mohd Yusoof Cheng Lay Teh Asmah Binti Mohd Xiang Ting Khor Liza Binti Mohd Isa Source Type: research

The economic burden of systemic lupus erythematosus in Taiwan
CONCLUSION: The findings demonstrated that the burden of SLE in Taiwan over a time horizon of 5 years is substantially high, mainly due to the consequences of economic loss as it affects women and men during their working age, in addition to the costs of SLE management and its consequences, such as flares, infection, and organ damage. Therefore, more attention should be paid to limiting the progression of SLE and the occurrence of flares, and further economic evaluations are necessary to assess novel treatment strategies that could control the disease.PMID:38468480 | DOI:10.1080/13696998.2024.2317118 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Song-Chou Hsieh Der-Yuan Chen Source Type: research

Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates
CONCLUSION: The addition of anifrolumab to SoC is a cost-effective option versus belimumab for the treatment of adult patients with active, autoantibody-positive SLE, despite being allocated to SoC. Cost-effectiveness was demonstrated by a reduction in complications and organ damage, which reflected costs and outcomes.PMID:38468481 | DOI:10.1080/13696998.2024.2320603 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 12, 2024 Category: Health Management Authors: Gihan Hamdy Elsisi Ahmed Abogamal Waleed Walid Al Shehhy Mohamed Farghaly Source Type: research